Gastrointestinal involvement in Fabry disease
Open Access
- 29 March 2024
- journal article
- Published by OAE Publishing Inc. in Rare Disease and Orphan Drugs Journal
- Vol. 3 (2)
Abstract
Fabry disease is an X-linked lysosomal storage disorder due to alpha-galactosidase A deficiency. This deficiency results in a progressive accumulation of globotriaosylceramide and related glycosphingolipids, particularly in vascular endothelial cells, renal cells, nerve cells, and cardiomyocytes. Gastrointestinal symptoms are frequent and can be extremely debilitating. It is known that most of the well-characterized gastrointestinal manifestations of Fabry disease are the result of the accumulation of glycosphingolipids, which causes vascular occlusion and malfunction of the peripheral and autonomic nervous system. Although improvement is noted in treating patients with enzyme replacement therapy and migalastat, some continue to experience symptoms after treatment; thus, it remains a significant cause of morbidity, necessitating concurrent adjuvant treatment. Current research is focused on clarifying the underlying dysmotility and further analyzing the correlation between the gut-brain axis, the histologic disease progression, and the clinical symptom presentation.Keywords
This publication has 50 references indexed in Scilit:
- Inhibitors of Glucosylceramide Synthase2023
- FABry Disease Patient-Reported Outcome-GastroIntestinal (FABPRO-GI): A new Fabry disease-specific gastrointestinal outcomes instrumentQuality of Life Research, 2021
- Non-specific gastrointestinal features: Could it be Fabry disease?Digestive and Liver Disease, 2018
- Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry2017
- Gastrointestinal Phenotype of Fabry Disease in a Patient with Pseudoobstruction Syndrome2011
- Misdiagnosis in Fabry DiseaseThe Journal of Pediatrics, 2010
- Safety and Efficacy of Enzyme Replacement Therapy with Agalsidase Beta: An International, Open-label Study in Pediatric Patients with Fabry DiseaseThe Journal of Pediatrics, 2008
- Gastrointestinal Symptoms in 342 Patients With Fabry Disease: Prevalence and Response to Enzyme Replacement TherapyClinical Gastroenterology and Hepatology, 2007
- Enzyme Replacement Therapy in Fabry DiseaseJAMA, 2001
- Lysosomal Storage DisordersArchives of Neurology, 1975